Neumora Therapeutics Reports $56.8 Million Net Loss in Q3 2025, Decreasing from Previous Year

Neumora Therapeutics, Inc. reported a net loss of $56.8 million for the third quarter of 2025, a decrease from a net loss of $72.5 million in the same period of the previous year. For the nine months ending September 30, 2025, the company recorded a net loss of $177.5 million, compared to a loss of $185.0 million for the same period in 2024. The reduction in losses is attributed to a significant decrease in operating expenses, which fell to $57.7 million in Q3 2025 from $76.6 million in Q3 2024, primarily driven by lower research and development costs.

Research and development expenses for the third quarter of 2025 were $40.5 million, down 33% from $60.6 million in the prior year. This decline was largely due to reduced costs associated with the navacaprant program, which saw a decrease of $7.1 million in manufacturing and clinical trial expenses. General and administrative expenses also decreased by 24% to $12.2 million, reflecting lower consulting and personnel-related costs. The company incurred $5.0 million in acquired in-process research and development expenses related to a milestone achievement under the Vanderbilt License Agreement.

As of September 30, 2025, Neumora's total assets were reported at $177.8 million, a significant decrease from $317.0 million at the end of 2024. The decline in assets was primarily due to a reduction in cash and cash equivalents, which fell to $129.1 million from $142.1 million. The company’s accumulated deficit increased to $1.12 billion, reflecting ongoing investments in research and development without generating revenue from product sales, as Neumora has not yet commercialized any products.

In terms of strategic developments, Neumora is advancing its clinical pipeline, including a Phase 3 program for navacaprant and a Phase 1b study for NMRA-511. The company has also entered into a loan agreement with K2 HealthVentures, providing up to $125 million in term loans, with $20 million drawn as of September 30, 2025. The company anticipates needing additional capital to support its ongoing operations and product development, as it expects to incur further losses in the future.

Looking ahead, Neumora plans to continue its focus on advancing its product candidates through clinical development and regulatory approval processes. The company believes its existing cash and marketable securities will be sufficient to fund operations for at least the next 12 months, but it acknowledges the need for future financing to support its long-term business objectives.